European Case Law Identifier: | ECLI:EP:BA:2017:T008416.20170127 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 27 January 2017 | ||||||||
Case number: | T 0084/16 | ||||||||
Application number: | 10762578.2 | ||||||||
IPC class: | A61K 38/16 A61K 9/00 A61P 7/00 |
||||||||
Language of proceedings: | EN | ||||||||
Distribution: | D | ||||||||
Download and more information: |
|
||||||||
Title of application: | PAR-1 activation by metalloproteinase-1 (MMP-1) | ||||||||
Applicant name: | Tufts Medical Center, Inc. | ||||||||
Opponent name: | - | ||||||||
Board: | 3.3.04 | ||||||||
Headnote: | - | ||||||||
Relevant legal provisions: |
|
||||||||
Keywords: | Admissibility of the appeal - (no) Error in the patent specification - (yes) Adversely affected by the grant decision - (no) Referral to the Enlarged Board of Appeal - (no) Exclusions from file inspection - (yes) |
||||||||
Catchwords: |
- |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t160084eu1.html
Date retrieved: 17 May 2021